Clinical review and treatment of select adverse effects of dopamine receptor agonists in parkinsons disease

Drugs and Aging

Volumn 27, Issue 4, 2010, Pages 295-310

  Wood, Lindy D ^a,b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Elder Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CAFFEINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHAMOMILE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUDROCORTISONE; GINGER EXTRACT; INDOMETACIN; LEVODOPA; METOCLOPRAMIDE; MIDODRINE; MODAFINIL; PEPPERMINT; PERGOLIDE; PRAMIPEXOLE; PROCHLORPERAZINE; PROMETHAZINE; QUETIAPINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRIMETHOBENZAMIDE; UNINDEXED DRUG;

ADJUVANT THERAPY; ANXIETY; BLEEDING; BRONCHOSPASM; CHILL; CLINICAL TRIAL; COMPULSION; CONSTIPATION; DEPRESSION; DIZZINESS; DROWSINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG PREFERENCE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSKINESIA; DYSPEPSIA; DYSURIA; EDEMA; FATIGUE; FOOD INTAKE; GINGER; HALLUCINATION; HEART PALPITATION; HEARTBURN; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; INSOMNIA; KIDNEY DYSFUNCTION; LUNG FIBROSIS; MOTOR DYSFUNCTION; NAUSEA; NAUSEA AND VOMITING; NERVOUSNESS; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PARKINSON DISEASE; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PRURITUS; PSYCHOSIS; RAYNAUD PHENOMENON; RETROPERITONEAL FIBROSIS; REVIEW; SALIVATION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; TACHYCARDIA; TREMOR; VALVULAR HEART DISEASE; VOMITING; WEIGHT GAIN;

COMPLEMENTARY THERAPIES; DOPAMINE AGONISTS; HUMANS; PARKINSON DISEASE;

EID: 77950669992     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11318330-000000000-00000     Document Type: Review

References (93)

1. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med 2003; 348: 1356-1364
2. Factor SA,WeinerWJ, editors. Parkinson's disease: diagnosis and clinical management. 2nd ed. New York: Demos, 2008
3. Fabbrini G, Brotchie JM, Grandas F, et al. Levodopainduced dyskinesias. Mov Disord 2007; 22 (10): 1379-1389
4. Chen JJ, Swope DM. Pharmacotherapy for Parkinson's disease. Pharmacotherapy 2007; 27: 161S-73S
5. Hubble JP. Long-term studies of dopamine agonists. Neurology 2002; 58 Suppl. 1: S42-50
6. Reichmann H. Long-term treatment with dopamine agonists in idiopathic Parkinson's disease. J Neurol 2000; 247 Suppl. 4: IV/17-19
7. Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole versus levodopa in early Parkinson disease. Arch Neurol 2009; 66 (5): 563-570
8. Hauser RA, Rascol O, Korczyn AD, et al. Ten-year followup of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007; 22 (16): 2409-2417
9. Katzenschlager R, Head J, Schrag A, et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008; 71: 474-480
10. Poewe W. Non-motor symptoms in Parkinson's disease. Eur J Neurol 2008; 15 Suppl. 1: 14-20
11. FDA. Public health advisory: pergolide (marketed as Permax). 2007 Mar 3 [online]. Available from URL: http:// www.fda.gov/Drugs/DrugSafety/ PublicHealthAdvisories/ ucm051285.html [Accessed 2010 Jan 18]
12. FDA. Neupro (rotigotine transdermal system). 2008 Apr 8 [online]. Available from URL: http://www.fda.gov/Safety/ MedWatch/SafetyInformation/ SafetyAlertsforHumanMedi calProducts/ucm094861.htm [Accessed 2010 Jan 18]
13. Tan EK, Jankovic J. Choosing dopamine agonists in Parkinson's disease. Clin Neuropharmacol 2001; 24 (5): 247-253
14. Lebrun-Frenay C, Borg M. Choosing the right dopamine agonist for patients with Parkinson's disease. Curr Med Res Opin 2002; 18 (4): 209-214
15. Junghanns S, Glockler T, Reichmann H. Switching and combining of dopamine agonists. J Neurol 2004; 251 Suppl. 6: VI/19-23
16. Obering CD, Chen JJ, Swope DM. Update on apomorphine for the rapid treatment of hypomobility ("off") episodes in Parkinson's disease. Pharmacotherapy 2006; 26 (6): 840-852
17. Reichmann H, Herting B, Muller A, et al. Switching and combining dopamine agonists. J Neural Transm 2003; 110: 1393-1400
18. Clinical Pharmacology [database]. Tampa (FL): Gold Standard, Inc., 2009 [online]. Available from URL: http: //www.clinicalpharmacology.com [Accessed 2009 Oct 14]
19. Parlodel® (bromocriptine mesylate tablets): US prescribing information. New York: Novartis, 2006
20. Mirapex® (pramipexole dihydrochloride tablets): US prescribing information. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals, Inc., 2009
21. Requip® (ropinirole tablets): US prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2009
22. Neupro® (rotigotine transdermal system): US prescribing information. Mequon (WI): Schwarz Pharma, LLC, 2004
23. Requip XL® (ropinirole extended release tablets): US prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2008
24. Stewart D, Morgan E, Burn D, et al. Dopamine agonist switching in Parkinson's disease. Hosp Med 2004; 65 (4): 215-219
25. Fahn S, Jankovic J, editors. Principles and practice of movement disorders. 2nd ed. Philadelphia (PA): Churchill Livingstone Elsevier, 2007
26. Etminan M, Gill S, Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. Drug Saf 2003; 26 (6): 439-444
27. Ernst E, Pittler MH. Efficacy of ginger for nausea and vomiting: a systematic review of randomized clinical trials. Br J Anaesth 2000; 84 (3): 367-371 (Pubitemid 30114135)
28. Antonini A, Cilia R. Behavioural adverse effects of dopaminergic treatments in Parkinson's disease: incidence, neurobiological basis, management and prevention. Drug Saf 2009; 32 (6): 475-488
29. Voon V, Potenza MN, Thomsen T. Medication-related impulse control and repetitive behaviors in Parkinson's disease. Curr Opin Neurol 2007; 20: 484-492 (Pubitemid 47051998)
30. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000; 15 (2): 201-211
31. Kujawa K, Leurgans S, Raman R, et al. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch Neurol 2000; 57: 1461-1463
32. Pathak A, Senard JM. Pharmacology of orthostatic hypotension in Parkinson's disease: from pathophysiology to management. Expert Rev Cardiovasc Ther 2004; 2 (3): 393-403
33. Schoffer KL, Henderson RD, O'Maley K, et al. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord 2007; 22 (11): 1543-1549
34. Apokyn® (apomorphine hydrochloride injection): US prescribing information. Brisbane (CA): Tercica, Inc., 2009
35. Ahmad N, Keith-Ferris J, Gooden E, et al. Making a case for domperidone in the treatment of gastrointestinal motility disorders. Curr Opin Pharmacol 2006; 6: 571-576
36. Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol 2007; 102: 2036-2045
37. Barone JA. Domperidone: a peripherally acting dopamine2- receptor antagonist. Ann Pharmacother 1999; 33: 429-440
38. Champion MC, Hartnett M, Yen M. Domperidone, a new dopamine antagonist. CMAJ 1986; 135: 457-461
39. Soykan I, Sarosiek I, Shifflett J, et al. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease. Mov Disord 1997; 12 (6): 952-957 (Pubitemid 27496773)
40. Natural Medicines Comprehensive Database. Stockton (CA): Therapeutic Research Faculty; 1995-2009 [online]. Available from URL: http://www. naturaldatabase.com/ (S(0db2djzcs0kgz045ma21zqva))/home.aspx?cs=&s=ND [Accessed 2009 Oct 15]
41. Berardi RR, editor. Handbook of nonprescription drugs: an interactive approach to self care. 15th ed.Washington, DC: American Pharmaceutical Association, 2006
42. Spirling LI, Daniels IR. Peppermint: more than just an after-dinner mint. J R Soc Promot Health 2001; 121 (1): 62-63
43. Arnulf I. Excessive daytime sleepiness in parkinsonism. Sleep Med Rev 2005; 9: 185-200
44. Kumar R. Approved and investigational uses of modafinil: an evidence-based review. Drugs 2008; 68 (13): 1803-1839
45. Factor SA, Friedman JH, Lannon MC, et al. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord 2001; 16 (1): 135-139
46. Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 996-1002
47. Chou KL. Adverse events from the treatment of Parkinson's disease. Neurol Clin 2008; 26: S65-83
48. Parkes JD. Domperidone and Parkinson's disease. Clin Neuropharmacol 1986; 9 (6): 517-532
49. Jost W. Gastrointestinal motility problems in patients with Parkinson's disease: effects of antiparkinsonian treatment and guidelines for management. Drugs Aging 1997; 10 (4): 249-258
50. Braun M, Cawello W, Boekens H, et al. Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine. Br J Clin Pharmacol 2008; 67 (2): 209-215
51. FDA. FDA talk paper: FDA warns against women using unapproved drug, domperidone, to increasemilk production. 2004 Jun 7 [online]. Available from URL: http://www.fda. gov/Drugs/DrugSafety/InformationbyDrugClass/ucm073070. htm [Accessed 2010 Jan 18]
52. Paus S, Brecht HM, Koster J, et al. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 2003; 18 (6): 659-667
53. Chaudhuri KR, Pal S, Brefel-Courbon C. 'Sleep attacks' or 'unintended sleep episodes' occur with dopamine agonists: is this a class effect? Drug Saf 2002; 25 (7): 473-483
54. Brodsky MA, Godbold J, Roth T, et al. Sleepiness in Parkinson's disease: a controlled study. Mov Disord 2003; 18 (6): 668-672
55. Hobson DE, Lang AE, Martin WR, et al. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 2002; 287: 455-463
56. Hogl B, Seppi K, Brandauer E. Increased daytime sleepiness in Parkinson's disease: a questionnaire survey. Mov Disord 2003; 18 (3): 319-323
57. Razmy A, Lang AE, Shapiro CM. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) versus newer (nonergot) dopamine agonists. Arch Neurol 2004; 61: 97-102
58. Roth T, Schwartz JRL, Hirshkowitz M, et al. Evaluation of the safety of modafinil for treatment of excessive sleepiness. J Clin Sleep Med 2007; 3 (6): 595-602
59. Valentino RM, Foldvary-Schaefer N. Modafinil in the treatment of excessive daytime sleepiness. Cleve Clin JMed 2007; 74 (8): 561-571
60. Ondo WG, Fayle R, Atassi F, et al. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry 2005; 76: 1636-1639
61. McKeon A, Josephs KA, Klos KJ, et al. Unusual compulsive behaviors primarily related to dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 2007; 13: 516-519
62. Driver-Dunckley ED, Boble BN, Hentz JG, et al. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol 2007; 30 (5): 249-255
63. Bostwick JM, Hecksel KA, Stevens SR, et al. Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease. Mayo Clin Proc 2009; 84 (4): 310-316
64. Weintraub D, Koester J, Potenza M, et al. Dopaminergic therapy and impulse control disorders in Parkinson's disease: top line results of a cross-sectional study of over 3000 patients [abstract]. Mov Disord 2008; 23 Suppl. 4: 38
65. Weintraub D. Dopamine and impulse control disorders in Parkinson's disease. Ann Neurol 2008; 64 Suppl.: S93-100
66. Mamikonyan E, Siderowf AD, Duda JE, et al. Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord 2007; 23 (1): 75-80
67. Grosset D. Dopamine agonists and therapy compliance. Neurol Sci 2008; 29: S375-6
68. Kimber TE, Thompson PD, Kiley MA. Resolution of dopamine dysregulation syndrome following cessation of dopamine agonist therapy in Parkinson's disease. J Clin Neurosci 2008; 15: 205-208
69. Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 2006; 21 (4): 524-529
70. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010; 67 (1): 58-63
71. Barnes J, David AS. Visual hallucinations in Parkinson's disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry 2001; 70: 727-733
72. Fenelon G, Mahieux F, Huon R, et al. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000; 123: 733-745
73. Ecker D, Unrath A, Kasubek J, et al. Dopamine agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study. BMC Neurol 2009; 9: 23-28
74. Biglan KM, Holloway RG, McDermott MP, et al. Risk factors for somnolence, edema, and hallucinations in early Parkinson's disease. Neurology 2007; 69: 187-195
75. Reddy S, Factor SA,Molho ES, et al. The effect of quetiapine on psychosis and motor function in Parkinsonian patients with and without dementia.Mov Disord 2002; 17 (4): 676-681
76. Fernandez HH, Trieschmann ME, Burke MA, et al. Longterm outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 2003; 18 (5): 510-514
77. Papapetropoulos S, Argyriou AA, Ellul J. Factors associated with drug-induced visual hallucinations in Parkinson's disease. J Neurol 2005; 252: 1223-1228
78. Fernandez HH, Friedman JH, Jacques C, et al. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 1999; 14 (3): 484-487
79. Ondo WG, Tintner R, Dat Voung K, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005; 20 (8): 958-963
80. MerimsD, BalasM, PeretzC, et al.Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol 2006; 29 (6): 331-337
81. Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson's disease patients: a doubleblind labeled study of 3 months duration. Mov Disord 2007; 22 (3): 313-318
82. Shotbolt P, Samuel M, Fox C, et al. A randomized controlled trial of quetiapine for psychosis in Parkinson's disease. Neuropsychiatr Dis Treat 2009; 5: 327-332
83. The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet 1999; 353: 2041-2042
84. Senard JM, Rai S, Lapeyre-Mestre M. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 63: 584-589
85. Senard JM, Brefel-Courbon C, Rascol O, et al. Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging 2001; 18 (7): 495-505
86. Goldstein DS, Pechnik S, Holmes C, et al. Association between supine hypertension and orthostatic hypotension in autonomic failure. Hypertension 2003; 42: 136-142
87. Lang AE. Acute orthostatic hypotension when starting dopamine agonist therapy in Parkinson disease: the role of domperidone therapy [letter]. Arch Neurol 2001; 58: 835
88. Abate G, Polimeni RM, Cuccurullo F, et al. Effects of indomethacin on postural hypotension in Parkinsonism. BMJ 1979; 2: 1466-1468 (Pubitemid 10162310)
89. Hoehn MM. Levodopa-induced postural hypotension: treatment with fludrocortisone. Arch Neurol 1975; 32: 50-51
90. Low PA, Gilden JL, Freeman R, et al. Efficacy of midodrine versus placebo in neurogenic orthostatic hypotension: a randomized, double-blind multicenter study. JAMA 1997; 277: 1046-1051
91. Jankovic J, Gilden JL, Hiner BC, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med 1993; 95: 38-48
92. Kleiner-Fisman G, Fisman DN. Risk factors for the development of pedal edema in patients using pramipexole. Arch Neurol 2007; 64: 820-824
93. Tan EK, Ondo W. Clinical characteristics of pramipexoleinduced peripheral edema. Arch Neurol 2000; 57: 729-732